Astec Lifesciences Ltd

₹ 1,265 0.20%

23 Apr 4:02 p.m.

About

The Company is into manufacturing of agrochemical active ingredients (technical), bulk and formulations, intermediate products and it sells its products in India as well as exports them to approximately 24 countries.
Astec also has undertaken a number of custom synthesis projects, for its clients in Europe, Japan and the US. It is present only in business to business sale (B2B).^[1] ^[2] ^[3]

Key Points

Product Portfolio
The company offers a range of products and intermediates, including fungicides, insecticides, herbicides, and various chemical compounds, serving global customers and including triazole fungicides, heterocyclic herbicides, sulfonylurea herbicides, synthetic pyrethroids, fluorinated compounds, halides, intermediates, ketones, ethers, alcohols, and many others. ^[1]

Website BSE NSE

Market Cap ₹ 2,479 Cr.
Current Price ₹ 1,265
High / Low ₹ 1,542 / 825
Stock P/E
Book Value ₹ 201
Dividend Yield 0.12 %
ROCE 7.82 %
ROE 6.36 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Debtor days have improved from 120 to 90.0 days.

Cons

Company has low interest coverage ratio.
The company has delivered a poor sales growth of 11.3% over past five years.
Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Agro Chemicals Industry: Pesticides / Agrochemicals - Indian

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023
	116	172	129	103	173	272	184	200	117	127	143	111	51
	100	134	104	81	130	207	159	166	105	122	140	114	69
Operating Profit	16	38	25	21	43	65	25	33	12	5	3	-3	-18
OPM %	13%	22%	19%	21%	25%	24%	14%	17%	10%	4%	2%	-3%	-36%
	3	2	1	1	2	7	3	4	4	3	2	1	1
Interest	1	1	2	2	3	3	4	5	6	6	6	6	6
Depreciation	7	7	7	8	9	11	9	8	9	8	9	9	9
Profit before tax	11	32	17	12	33	58	15	25	1	-6	-11	-18	-32
Tax %	37%	26%	26%	26%	25%	26%	25%	25%	31%	20%	26%	24%	24%
	7	24	13	9	25	43	11	18	1	-5	-8	-13	-24
EPS in Rs	3.61	12.23	6.63	4.63	12.63	21.97	5.82	9.34	0.43	-2.54	-4.18	-6.85	-12.41
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
	112	174	207	267	233	299	368	431	523	555	677	628	431
	97	146	171	213	201	236	299	354	437	443	522	551	445
Operating Profit	16	28	35	54	32	63	69	76	85	112	154	77	-13
OPM %	14%	16%	17%	20%	14%	21%	19%	18%	16%	20%	23%	12%	-3%
	1	0	-0	-16	4	-8	12	11	12	8	10	13	6
Interest	6	7	9	13	13	12	11	12	13	5	9	21	25
Depreciation	9	12	15	13	10	14	15	19	23	26	34	34	35
Profit before tax	2	9	11	13	12	29	56	56	61	89	121	35	-67
Tax %	29%	32%	22%	-17%	59%	33%	37%	36%	23%	27%	26%	27%
	1	6	9	15	5	19	35	36	48	65	90	26	-51
EPS in Rs	0.81	3.30	4.68	7.60	2.55	9.80	17.87	18.28	24.28	33.21	45.85	13.04	-25.98
Dividend Payout %	62%	23%	21%	16%	0%	15%	8%	8%	6%	5%	3%	12%

Compounded Sales Growth
10 Years:	14%
5 Years:	11%
3 Years:	6%
TTM:	-44%

Compounded Profit Growth
10 Years:	16%
5 Years:	-4%
3 Years:	-18%
TTM:	-169%

Stock Price CAGR
10 Years:	39%
5 Years:	20%
3 Years:	5%
1 Year:	-7%

Return on Equity
10 Years:	17%
5 Years:	18%
3 Years:	17%
Last Year:	6%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Sep 2023
Equity Capital	17	18	19	19	19	20	20	20	20	20	20	20	20
Reserves	80	87	95	116	99	119	150	183	227	290	377	400	375
	74	73	83	93	127	127	125	176	99	187	279	341	431
	60	83	88	133	85	69	119	83	226	181	221	219	83
Total Liabilities	231	261	284	362	330	334	413	461	572	678	897	979	909
	76	121	132	133	95	103	115	167	194	213	340	318	408
CWIP	44	13	6	12	20	8	42	19	24	116	23	127	128
Investments	12	0	0	0	0	0	0	0	0	0	0	0	0
	100	127	146	216	215	223	256	275	354	349	534	534	374
Total Assets	231	261	284	362	330	334	413	461	572	678	897	979	909

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
	16	15	7	-13	19	65	15	168	-8	24	75
	-13	-19	-19	-17	-18	-49	-52	-74	-73	-104	-113
	-2	3	12	31	-1	-18	37	-95	81	80	38
Net Cash Flow	1	-1	-0	2	1	-3	-0	0	0	0	-0

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Debtor Days	103	131	91	142	126	135	122	103	112	123	148	90
Inventory Days	237	145	192	147	177	133	122	121	131	113	176	268
Days Payable	146	132	114	179	169	116	155	83	218	137	179	161
Cash Conversion Cycle	195	145	168	109	134	152	89	142	25	100	145	197
Working Capital Days	179	122	125	125	142	154	115	147	77	101	163	175
ROCE %	5%	9%	11%	20%	12%	20%	22%	20%	20%	22%	22%	8%

Shareholding Pattern

Numbers in percentages

1 Recently

	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
	65.20%	65.20%	65.19%	65.29%	65.29%	66.77%	66.76%	66.76%	66.76%	66.75%	66.75%	66.75%
	0.19%	0.22%	0.29%	0.32%	0.48%	1.53%	2.19%	2.29%	1.95%	1.33%	1.28%	1.25%
	10.93%	12.21%	12.74%	12.56%	11.79%	9.82%	9.57%	10.58%	10.15%	10.16%	9.74%	7.88%
	23.68%	22.37%	21.78%	21.83%	22.45%	21.87%	21.49%	20.37%	21.13%	21.74%	22.22%	24.12%
No. of Shareholders	22,817	21,073	19,002	16,951	17,433	17,632	19,545	17,809	18,703	18,722	19,244	19,848

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
	65.54%	67.31%	67.62%	71.33%	65.23%	65.29%	66.76%	66.75%
	1.87%	0.77%	0.89%	0.84%	0.25%	0.32%	2.29%	1.25%
	0.27%	2.17%	2.10%	0.51%	10.67%	12.56%	10.58%	7.88%
	0.00%	0.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	32.32%	29.74%	29.39%	27.32%	23.85%	21.83%	20.37%	24.12%
No. of Shareholders	11,907	13,197	12,771	10,701	19,872	16,951	17,809	19,848

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

DRHP

Credit ratings

Concalls

Nov 2022
Transcript
PPT
Nov 2022
Transcript
PPT
May 2022
Transcript
PPT
Nov 2021
Transcript
PPT
Aug 2021
Transcript
PPT
Feb 2021
Transcript
PPT